NewAmsterdam Pharma Co N.V.

NAMS

NewAmsterdam Pharma Co N.V.

NAMS

Insider Sentiment (TTM):

Last Purchase:2025-09-15Last Sale:2026-06-22Shares Purchased (TTM):1,920Shares Sold (TTM):1,295,822

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:118,289,453Shares Outstanding:121,716,006Institutional Ownership Pct.:97.18%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31
Assets
Cash	-	-	-	-	-	-	-	423	431	481	340
Cash And Cash Equivalents At Carrying Value	424	458	490	538	564	748	772	423	-	-	340
Assets Current
Assets Current	659	658	676	732	770	817	863	438	445	488	347
Prepaid Expense And Other Assets Current	24	21	38	28	31	9	24	15	15	7	6
Marketable Securities Current	210	178	146	165	175	60	62	-	-	-	-
Restricted Cash Current	1	1	1	1	-	-	-	-	-	-	-
Marketable Securities Noncurrent	44	71	93	53	44	-	-	-	-	-	-
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	0	1	0	0
Intangible Assets Net Including Goodwill	0	0	0	0	0	1	1	1	1	0	0
Prepaid Expense Noncurrent	-	3	-	-	-	-	-	-	0	0	0
Assets	704	733	769	786	815	818	865	439	447	488	347
Liabilities And Stockhold…
Accounts Payable Current	5	8	9	4	6	6	5	7	5	9	17
Accounts Payable And Other Accrued Liabilities Cur…	10	5	15	10	9	8	14	11	10	10	11
Liabilities Current
Deferred Revenue Current	3	4	4	-	-	3	6	4	6	8	9
Liabilities Current	73	67	86	58	37	41	107	41	45	60	50
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0
Derivative Liabilities Current	54	50	57	44	21	24	38	19	24	33	13
Deferred Revenue Noncurrent	-	-	-	-	-	-	-	-	0	0	1
Operating Lease Liability Noncurrent	0	-	0	0	0	0	0	0	0	-	-
Derivative Liabilities Noncurrent	-	-	-	-	-	-	-	19	13	16	8
Liabilities	73	67	86	58	37	41	107	60	59	77	59
Common Stock Value	15	15	14	14	14	14	13	11	11	11	10
Additional Paid In Capital Common Stock	1,488	1,457	1,427	1,397	1,376	1,357	1,298	829	822	807	591
Stockholders Equity
Stockholders Equity	631	665	683	728	778	777	758	379	387	412	288
Retained Earnings Accumulated Deficit	-875	-811	-762	-687	-615	-598	-559	-466	-450	-411	-317
Accumulated Other Comprehensive Income Loss Net Of…	4	4	5	5	4	4	4	4	4	4	4
Liabilities And Stockholders Equity	704	733	769	786	815	818	865	439	447	488	347
Common Stock Par Or Stated Value Per Share	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400
Common Stock Shares Issued	118	117	114	113	113	112	108	92	90	90	82
Shares Outstanding	118	117	114	113	113	112	108	92	90	90	82

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-3.36%	-4.62%	-14.95%	-	-	-	-	-	-	-	-	-
2025	-6.02%	-3.63%	22.47%	1.82%	20.66%	51.23%	8.33%	-7.49%	-12.60%	-19.97%	-2.80%	8.31%
2024	-13.95%	-11.84%	-13.45%	4.85%	3.64%	21.90%	-8.86%	18.73%	8.36%	21.11%	-17.10%	-4.21%
2023	-	-	-	-	-	-	-	-	-	-5.72%	-15.62%	-14.94%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31
Liquidity Ratios
Current Ratio	9.03	9.76	7.88	12.57	21.08	19.98	8.08	10.61	9.83	8.17	6.95
Quick Ratio	8.70	9.45	7.43	12.09	20.24	19.76	7.85	10.25	9.51	8.06	6.82
Working Capital	586.23M	590.62M	589.91M	674.06M	733.34M	776.39M	756.50M	396.62M	400.05M	428.10M	296.89M
Leverage & Debt
Debt to Equity	0.12	0.10	0.13	0.08	0.05	0.05	0.14	0.16	0.15	0.19	0.20
Debt Ratio	0.10	0.09	0.11	0.07	0.04	0.05	0.12	0.14	0.13	0.16	0.17
Efficiency & Turnover
Asset Turnover TTM	0.01	0.03	0.03	0.06	0.10	0.07	0.08	0.07	-	-	-
Per Share Metrics
Diluted EPS TTM	-2.10	-1.75	-1.72	-1.86	-1.40	-1.61	-2.56	-1.58	-	-	-
Free Cash Flow Per Share TTM	-1.21	-1.17	-1.25	-0.91	-0.74	-1.21	-1.69	-1.28	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Margin Metrics
Operating Profit Margin TTM	-3,432.20%	-953.59%	-1,002.90%	-575.81%	-269.96%	-402.49%	-386.91%	-405.78%	-	-	-
Net Profit Margin TTM	-3,644.21%	-942.76%	-905.74%	-627.28%	-258.91%	-397.45%	-530.25%	-455.68%	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	-88.87%	-52.13%	-50.61%	7.48%	-	-	-	-	-	-	-
Net Income Growth (1Y)	56.60%	13.54%	-15.64%	47.95%	-	-	-	-	-	-	-
EPS Growth (1Y)	50.49%	8.33%	-32.78%	17.81%	-	-	-	-	-	-	-
Valuation Metrics
P/E TTM	-16.11	-18.31	-20.38	-15.31	-12.96	-12.69	-10.04	-10.53	-	-	-
P/B TTM	6.62	5.86	6.08	4.65	2.76	3.06	3.20	4.15	4.70	5.08	3.18
P/S TTM	587.14	172.66	184.61	96.03	33.54	50.43	53.22	47.97	-	-	-
Market Cap	4.18B	3.90B	4.15B	3.38B	2.15B	2.38B	2.43B	1.57B	1.82B	2.09B	917.75M
Enterprise Value	3.76B	3.44B	3.66B	2.85B	1.58B	1.63B	1.65B	1.15B	1.39B	1.61B	577.30M
Calculated Values
Free Cash Flow TTM	-149.56M	-142.19M	-148.03M	-108.05M	-87.82M	-140.73M	-159.24M	-121.75M	-	-	-
Net Debt	-424.15M	-457.61M	-490.00M	-538.41M	-563.86M	-748.42M	-771.74M	-422.73M	-430.71M	-481.15M	-340.45M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-22Sale

Owner: Kooij, Louise Frederika

Title: Chief Accounting Officer

Shares: 40,000

Price/Share: $30.46

Value: $1,218,400.00

Shares Owned: 24,353

Relationship: Officer

Ownership: Direct

2026-05-26Sale

Owner: Kooij, Louise Frederika

Title: Chief Accounting Officer

Shares: 65,000

Price/Share: $35.69

Value: $2,319,850.00

Shares Owned: 24,353

Relationship: Officer

Ownership: Direct

2026-03-11Sale

Owner: Lange, Louis G

Title: -

Shares: 44,619

Price/Share: $30.82

Value: $1,375,157.58

Shares Owned: 10,360

Relationship: Director

Ownership: Direct

2026-03-09Sale

Owner: Kastelein, Johannes Jacob…

Title: Chief Scientific Officer

Shares: 101,409

Price/Share: $30.29

Value: $3,071,678.61

Shares Owned: 69,302

Relationship: Director,Officer

Ownership: Indirect

2026-03-06Sale

Owner: Lange, Louis G

Title: -

Shares: 28,186

Price/Share: $29.41

Value: $828,950.26

Shares Owned: -

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-22	Kooij, Louise Frederika	Officer	Chief Accounting Officer	Direct	Sale	40,000	30.46	$1,218,400.00	24,353	4
2026-05-26	Kooij, Louise Frederika	Officer	Chief Accounting Officer	Direct	Sale	65,000	35.69	$2,319,850.00	24,353	4
2026-03-11	Lange, Louis G	Director	-	Direct	Sale	44,619	30.82	$1,375,157.58	10,360	4
2026-03-09	Kastelein, Johannes Jacob…	Director,Officer	Chief Scientific Officer	Indirect	Sale	101,409	30.29	$3,071,678.61	69,302	4
2026-03-06	Lange, Louis G	Director	-	Indirect	Sale	28,186	29.41	$828,950.26	0	4
2026-03-02	Davidson, Michael H.	Director,Officer	Chief Executive Officer	Direct	Sale	443,707	33.25	$14,753,257.75	174,144	4
2026-02-26	Davidson, Michael H.	Director,Officer	Chief Executive Officer	Direct	Sale	183,332	34.03	$6,238,787.96	174,144	4
2026-02-20	Kastelein, Johannes Jacob…	Director,Officer	Chief Scientific Officer	Direct	Sale	45,481	35.23	$1,602,295.63	53,500	4
2026-01-28	Kooij, Louise Frederika	Officer	Chief Accounting Officer	Direct	Sale	32,612	31.80	$1,037,061.60	24,353	4
2026-01-26	Kooij, Louise Frederika	Officer	Chief Accounting Officer	Direct	Sale	34,400	33.11	$1,138,984.00	24,353	4
2026-01-21	Somaiya, Mayur Ian	Officer	Chief Financial Officer	Direct	Sale	39,784	33.52	$1,333,559.68	58,382	4
2026-01-07	Davidson, Michael H.	Director,Officer	Chief Executive Officer	Direct	Sale	11,582	-	-	378,859	4
2026-01-05	Somaiya, Mayur Ian	Officer	Chief Financial Officer	Direct	Sale	5,118	33.25	$170,173.50	32,882	4
2026-01-05	Kastelein, Johannes Jacob…	Director,Officer	Chief Scientific Officer	Direct	Sale	6,000	33.25	$199,500.00	73,481	4
2026-01-05	Kooij, Louise Frederika	Officer	Chief Accounting Officer	Direct	Sale	2,647	33.25	$88,012.75	12,353	4
2025-12-26	Kooij, Louise Frederika	Officer	Chief Accounting Officer	Direct	Sale	43,872	35.30	$1,548,681.60	15,000	4
2025-09-15	Topper, James N	Director	-	Indirect	Purchase	660	23.70	$15,642.00	3,028,524	4
2025-09-09	Kooij, Louise Frederika	Officer	Chief Accounting Officer	Direct	Sale	150,000	25.71	$3,856,500.00	15,000	4
2025-09-08	Topper, James N	Director	-	Indirect	Purchase	1,260	24.99	$31,487.40	3,027,864	4
2025-09-03	Kooij, Louise Frederika	Officer	Chief Accounting Officer	Direct	Sale	18,073	25.09	$453,451.57	15,000	4
2025-08-25	Kooij, Louise Frederika	Officer	Chief Accounting Officer	Direct	Sale	8,269	24.86	$205,567.34	15,000	4
2025-08-22	Kastelein, Johannes Jacob…	Director,Officer	Chief Scientific Officer	Indirect	Sale	50,000	25.28	$1,264,000.00	69,302	4
2025-08-11	Topper, James N	Director	-	Indirect	Purchase	471	23.98	$11,294.58	3,026,604	4
2025-07-16	Kling, Douglas F	Officer	Chief Operating Officer	Direct	Sale	51,043	21.10	$1,077,007.30	44,000	4
2025-06-25	Topper, James N	Director	-	Indirect	Purchase	1,260	18.26	$23,007.60	3,026,133	4
2025-06-16	Topper, James N	Director	-	Indirect	Purchase	8,584	19.50	$167,388.00	3,022,153	4
2025-06-16	Kling, Douglas F	Officer	Chief Operating Officer	Direct	Sale	100,000	19.47	$1,947,000.00	44,000	4
2025-05-15	Kling, Douglas F	Officer	Chief Operating Officer	Direct	Sale	100,000	-	-	44,000	4
2025-04-15	Kling, Douglas F	Officer	Chief Operating Officer	Direct	Sale	100,000	-	-	44,000	4
2025-03-26	Davidson, Michael H.	Director,Officer	Chief Executive Officer	Direct	Sale	12,258	-	-	390,441	4
2025-03-26	Kling, Douglas F	Officer	Chief Operating Officer	Direct	Sale	16,539	-	-	44,000	4
2025-03-26	Topper, James N	Director	-	Indirect	Purchase	1,135	22.49	$25,526.15	3,013,569	4
2025-03-17	Kling, Douglas F	Officer	Chief Operating Officer	Direct	Sale	100,000	-	-	44,000	4
2025-03-04	Kooij, Louise Frederika	Officer	Chief Accounting Officer	Direct	Sale	150,000	20.37	$3,055,500.00	15,000	4
2025-03-04	Topper, James N	Director	-	Indirect	Purchase	4,005	21.02	$84,185.10	3,012,434	4
2025-02-19	Kling, Douglas F	Officer	Chief Operating Officer	Direct	Sale	9,218	-	-	44,000	4
2025-01-30	Kling, Douglas F	Officer	Chief Operating Officer	Direct	Sale	13,578	-	-	44,000	4
2025-01-28	Somaiya, Mayur Ian	Officer	Chief Financial Officer	Direct	Sale	14,900	-	-	38,000	4
2025-01-28	Kling, Douglas F	Officer	Chief Operating Officer	Direct	Sale	25,385	-	-	44,000	4
2024-12-30	Forgrowth, Nap B.V., Forb…	TenPercentOwner	-	Indirect	Sale	29,846	25.54	$762,266.84	10,656,172	4
2024-12-27	Forbion, Capital Fund Iv …	TenPercentOwner	-	Indirect	Sale	41,472	25.95	$1,076,198.40	10,686,018	4
2024-12-24	Forbion, Iv Management B.…	TenPercentOwner	-	Indirect	Sale	16,164	25.66	$414,768.24	10,760,928	4
2024-12-19	Forgrowth, Nap B.V., Forb…	TenPercentOwner	-	Indirect	Sale	56,506	25.45	$1,438,077.70	10,851,996	4
2024-12-17	Forbion, Iv Management B.…	TenPercentOwner	-	Indirect	Sale	114,384	26.02	$2,976,271.68	11,009,230	4
2024-12-13	Forbion, Iv Management B.…	TenPercentOwner	-	Indirect	Sale	25,751	25.01	$644,032.51	11,124,710	4
2024-12-11	Forbion, Growth Managemen…	TenPercentOwner	-	Indirect	Sale	154,038	26.26	$4,045,037.88	11,316,472	4
2024-11-18	Forgrowth, Nap B.V., Forb…	TenPercentOwner	-	Indirect	Sale	33,273	25.08	$834,486.84	11,778,760	4
2024-11-14	Forbion, Capital Fund Iv …	TenPercentOwner	-	Indirect	Sale	9,832	25.01	$245,898.32	11,820,563	4
2024-10-01	Kooij, Louise Frederika	Officer	Chief Accounting Officer	Direct	Sale	45,000	15.72	$707,400.00	0	4
2024-09-26	Audet, Juliette Berangere	Officer	Chief Business Officer	Direct	Purchase	1,104	15.70	$17,332.80	1,104	4
2024-08-20	Davidson, Michael H.	Director,Officer	Chief Executive Officer	Direct	Purchase	5,000	16.27	$81,350.00	209,784	4
2024-06-20	Davidson, Michael H.	Director,Officer	Chief Executive Officer	Direct	Purchase	5,000	17.26	$86,300.00	204,784	4
2024-03-26	Kastelein, Johannes Jacob…	Director,Officer	Chief Scientific Officer	Indirect	Sale	190,476	21.50	$4,095,234.00	0	4
2024-03-26	Topper, James N	Director	-	Indirect	Purchase	8,429	21.50	$181,223.50	3,008,429	4
2024-02-13	Lange, Louis G	Director	-	Indirect	Purchase	5,000	19.00	$95,000.00	24,878	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

97.18%

Inst. Shares: 118,289,453

Shares Outstanding: 121,716,006

2025-12-31

96.66%

Inst. Shares: 114,473,969

Shares Outstanding: 118,424,231

2025-09-30

99.25%

Inst. Shares: 118,103,951

Shares Outstanding: 119,000,266

2025-06-30

97.09%

Inst. Shares: 115,104,559

Shares Outstanding: 118,556,492

2025-03-31

94.69%

Inst. Shares: 109,961,376

Shares Outstanding: 116,124,941

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	118,289,453	121,716,006	97.18%
2025-12-31	114,473,969	118,424,231	96.66%
2025-09-30	118,103,951	119,000,266	99.25%
2025-06-30	115,104,559	118,556,492	97.09%
2025-03-31	109,961,376	116,124,941	94.69%
2024-12-31	97,879,101	94,358,067	103.73%
2024-09-30	76,680,356	94,754,140	80.93%
2024-06-30	71,951,898	94,711,604	75.97%
2024-03-31	71,914,992	88,380,230	81.37%
2023-12-31	50,065,207	82,161,956	60.93%
2023-09-30	50,491,094	82,161,956	61.45%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

NewAmsterdam Pharma Co N.V. (NAMS) — SEC Financial Statements & Analysis

NewAmsterdam Pharma Co N.V. (NAMS) is a pharmaceutical preparations company, incorporated in P7. NewAmsterdam Pharma Co N.V. trades on Nasdaq as: NAMS, NAMSW. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), NewAmsterdam Pharma Co N.V. reported a -88.87% year-over-year revenue growth, a Debt-to-Equity ratio of 0.12x, a Price-to-Sales (P/S) ratio of 587.14x (TTM), a Price-to-Book (P/B) ratio of 6.62x (TTM), at a market cap of $4.18B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -88.87%
Debt To Equity: 0.12x
P/S TTM: 587.14x
P/B TTM: 6.62x
Market Cap: $4.18B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is NewAmsterdam Pharma Co N.V. in?

NewAmsterdam Pharma Co N.V. (NAMS) operates in the Pharmaceutical Preparations industry.

What is NAMS's market cap?

NewAmsterdam Pharma Co N.V. (NAMS) has a market capitalization of $4.18B as of 2026-06-30.

What exchange does NAMS trade on?

NewAmsterdam Pharma Co N.V. (NAMS) trades on the Nasdaq.

Where is NewAmsterdam Pharma Co N.V. incorporated?

NewAmsterdam Pharma Co N.V. is incorporated in Netherlands.